MasterClass Launches a Class on Dopamine to Help Members Balance Pleasure and Pain in an Overloaded World 
Mersana Therapeutics Announces 1-for-25 Reverse Stock Split
CAMBRIDGE, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the...
Liminatus Pharma Inc. Takes Next Step in Evaluating Digital Asset-Linked Capital Strategy
Agreement with Digital Offering Advances Company's plan to assess innovative treasury-backed financing pathsLA PALMA, Calif., July 24, 2025 (GLOBE NEWSWIRE)...
ICU Medical Announces Time of Second Quarter 2025 Earnings Conference Call
SAN CLEMENTE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture...
Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 7, 2025
SEATTLE and VANCOUVER, British Columbia, July 24, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty...
iSpecimen Inc. Announces Pricing of $4 Million Underwritten Offering
WOBURN, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace...
Trinity Biotech Unveils CGM+: An AI-Native Platform Targeting the $260 Billion AI Wearable Market
WILSONVILLE, Ore. and DUBLIN, July 24, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused...
Natural Appetite Suppressant: Why PhenQ Is the Safer Choice Over Weight Loss Injections in 2025
Phenq Phenq Newark, NJ, July 24, 2025 (GLOBE NEWSWIRE) -- PhenQ Leads the 2025 Weight Loss Revolution with a Science-Backed...
Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer
NEEDHAM, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical...
BioVie Presented Data Highlighting that Patients Treated with Bezisterim Potentially Experienced an Age Deceleration Advantage Compared to Placebo on 10 Different Biological Clocks at the 2nd World Conference on Aging and Gerontology
Bezisterim treatment appears to be associated with changes in DNA methylation of over 100 genes related to aging and diseases...
4DMT Announces Presentations at 43rd Annual Scientific Meeting of the American Society of Retina Specialists
EMERYVILLE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology...
Jeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the Décolleté
KB304 designed to deliver collagen and elastin to restore skin naturally Conference call to discuss results scheduled for Thursday, July...
Collegium to Report Second Quarter 2025 Financial Results on August 7, 2025
STOUGHTON, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report second quarter...
Pacira to Report Second Quarter 2025 Financial Results on Tuesday August 5, 2025
BRISBANE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to...
Cidara Therapeutics to Report Second Quarter 2025 Financial Results and Host Quarterly Conference Call on August 7, 2025
SAN DIEGO, July 24, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak®...
Solésence To Report Second Quarter 2025 Financial Results and Host a Conference Call
ROMEOVILLE, Ill., July 24, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across...
Matchpoint Therapeutics Announces Exclusive Option and License Agreement with Novartis to Develop Oral Inhibitors for Multiple Inflammatory Diseases
Matchpoint to receive up to $60 million in upfront payment and research funding, with up to $1 billion in total...
Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus
-Topline Readout Expected in Q3 2026- SOUTH SAN FRANCISCO, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS),...
Regeneron Announces the 2025 Winners of the Regeneron Prize for Creative Innovation
TARRYTOWN, N.Y., July 24, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the winners of the 13th annual...
Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study
– Peer-reviewed publication in Annals of Clinical and Translational Neurology highlights the use of the MSA Atrophy Index developed to...
The Joint Corp. to Host Conference Call on Thursday, August 7th to Discuss Second Quarter 2025 Results
SCOTTSDALE, Ariz., July 24, 2025 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT) the nation's largest franchisor of chiropractic care...